Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) have been assigned a consensus rating of “Buy” from the ten research firms that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $4.46.

Separately, Zacks Investment Research lowered shares of Tandem Diabetes Care from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd.

COPYRIGHT VIOLATION NOTICE: “Tandem Diabetes Care, Inc. (TNDM) Receives $4.46 Consensus Target Price from Analysts” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/03/tandem-diabetes-care-inc-tndm-receives-4-46-consensus-target-price-from-analysts.html.

A number of hedge funds have recently made changes to their positions in TNDM. Vanguard Group Inc. lifted its holdings in shares of Tandem Diabetes Care by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock worth $987,000 after acquiring an additional 32,991 shares during the last quarter. Bank of America Corp DE boosted its holdings in Tandem Diabetes Care by 88.6% during the 1st quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock valued at $1,032,000 after acquiring an additional 404,452 shares during the period. Russell Investments Group Ltd. boosted its holdings in Tandem Diabetes Care by 93.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 581,245 shares of the medical device company’s stock valued at $465,000 after acquiring an additional 280,551 shares during the period. Paulson & CO. Inc. acquired a new position in Tandem Diabetes Care in the 1st quarter valued at about $600,000. Finally, Keybank National Association OH grew its position in Tandem Diabetes Care by 32.7% in the 2nd quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock valued at $235,000 after acquiring an additional 72,177 shares in the last quarter. 36.64% of the stock is owned by institutional investors.

Shares of Tandem Diabetes Care (TNDM) traded down 0.9200% during trading on Friday, hitting $0.7431. 884,687 shares of the company’s stock were exchanged. The company’s market cap is $37.32 million. The company has a 50-day moving average of $0.68 and a 200-day moving average of $0.83. Tandem Diabetes Care has a 12-month low of $0.39 and a 12-month high of $8.10.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Thursday, July 27th. The medical device company reported ($0.44) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.04. The firm had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $21.74 million. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 110.70%. The firm’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.60) earnings per share. On average, equities analysts expect that Tandem Diabetes Care will post ($1.79) earnings per share for the current fiscal year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Stock Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related stocks with our FREE daily email newsletter.